Anti-FCG2A/ FCGR2A/ CD32 monoclonal antibody
Anti-FCG2A/ FCGR2A/ CD32 antibody for FACS & in-vivo assay
Go to FCGR2A/FCGR2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T22212-Ab-1/ GM-Tg-hg-T22212-Ab-2 | Anti-Human FCGR2A monoclonal antibody | Human |
GM-Tg-rg-T22212-Ab-1/ GM-Tg-rg-T22212-Ab-2 | Anti-Rat FCGR2A monoclonal antibody | Rat |
GM-Tg-mg-T22212-Ab-1/ GM-Tg-mg-T22212-Ab-2 | Anti-Mouse FCGR2A monoclonal antibody | Mouse |
GM-Tg-cynog-T22212-Ab-1/ GM-Tg-cynog-T22212-Ab-2 | Anti-Cynomolgus/ Rhesus macaque FCGR2A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T22212-Ab-1/ GM-Tg-felg-T22212-Ab-2 | Anti-Feline FCGR2A monoclonal antibody | Feline |
GM-Tg-cang-T22212-Ab-1/ GM-Tg-cang-T22212-Ab-2 | Anti-Canine FCGR2A monoclonal antibody | Canine |
GM-Tg-bovg-T22212-Ab-1/ GM-Tg-bovg-T22212-Ab-2 | Anti-Bovine FCGR2A monoclonal antibody | Bovine |
GM-Tg-equg-T22212-Ab-1/ GM-Tg-equg-T22212-Ab-2 | Anti-Equine FCGR2A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T22212-Ab-1/ GM-Tg-hg-T22212-Ab-2; GM-Tg-rg-T22212-Ab-1/ GM-Tg-rg-T22212-Ab-2; GM-Tg-mg-T22212-Ab-1/ GM-Tg-mg-T22212-Ab-2; GM-Tg-cynog-T22212-Ab-1/ GM-Tg-cynog-T22212-Ab-2; GM-Tg-felg-T22212-Ab-1/ GM-Tg-felg-T22212-Ab-2; GM-Tg-cang-T22212-Ab-1/ GM-Tg-cang-T22212-Ab-2; GM-Tg-bovg-T22212-Ab-1/ GM-Tg-bovg-T22212-Ab-2; GM-Tg-equg-T22212-Ab-1/ GM-Tg-equg-T22212-Ab-2 |
Products Name | Anti-FCGR2A monoclonal antibody |
Format | mab |
Target Name | FCGR2A |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-FCGR2A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species FCG2A/ FCGR2A/ CD32 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP004748 | human FCGR2A Lentivirus plasmid |
ORF Viral Vector | vGMLP004748 | human FCGR2A Lentivirus particle |
Target information
Target ID | GM-T22212 |
Target Name | FCGR2A |
Gene ID | 2212,719996 |
Gene Symbol and Synonyms | CD32,CD32A,CDw32,FCG2,FcgammaRIIa,FcGR,FCGR2,FCGR2A,FCGR2A1,FGCR,IGFR2 |
Uniprot Accession | P12318 |
Uniprot Entry Name | FCG2A_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target |
Disease | Cancer |
Gene Ensembl | ENSG00000143226 |
Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
The target: FCGR2A, gene name: FCGR2A, also named as CD32, CD32A, CDw32, FCG2, FCGR21, FcGR, IGFR2, FCGR2A. This gene encodes one member of a family of immunoglobulin Fc receptor genes found on the surface of many immune response cells. The protein encoded by this gene is a cell surface receptor found on phagocytic cells such as macrophages and neutrophils, and is involved in the process of phagocytosis and clearing of immune complexes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.